The expectation is that therapeutic strategies based on PARP inhibition will prove effective in treating ovarian cancer, as well as breast cancer, characterized by the loss of BRCA1/2 function, irrespective of whether the tumors are familial or sporadic in nature. Here, BRCA1 is linked to ovarian carcinoma.